LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Search

Charles River Laboratories International Inc

Fermé

SecteurSoins de santé

151.8 -2.4

Résumé

Variation du prix de l'action

24h

Actuel

Min

151.57

Max

158.21

Chiffres clés

By Trading Economics

Revenu

-332M

-277M

Ventes

-11M

994M

BPA

2.43

Marge bénéficiaire

-27.816

Employés

18,300

EBITDA

730K

198M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+32.44% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

772M

8.7B

Ouverture précédente

154.2

Clôture précédente

151.8

Sentiment de l'Actualité

By Acuity

10%

90%

9 / 351 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 mars 2026, 21:37 UTC

Acquisitions, Fusions, Rachats

Lensar and Alcon Agree to Terminate Merger

16 mars 2026, 19:06 UTC

Principaux Événements d'Actualité

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16 mars 2026, 17:44 UTC

Acquisitions, Fusions, Rachats

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16 mars 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 mars 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Oil Prices Decline -- Market Talk

16 mars 2026, 23:37 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16 mars 2026, 23:05 UTC

Market Talk

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16 mars 2026, 21:56 UTC

Market Talk

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16 mars 2026, 21:41 UTC

Market Talk
Principaux Événements d'Actualité

Global Equities Roundup: Market Talk

16 mars 2026, 21:41 UTC

Market Talk
Principaux Événements d'Actualité

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16 mars 2026, 20:59 UTC

Acquisitions, Fusions, Rachats

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16 mars 2026, 20:59 UTC

Acquisitions, Fusions, Rachats

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16 mars 2026, 20:59 UTC

Acquisitions, Fusions, Rachats

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16 mars 2026, 20:57 UTC

Acquisitions, Fusions, Rachats

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16 mars 2026, 20:51 UTC

Acquisitions, Fusions, Rachats

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16 mars 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 mars 2026, 20:50 UTC

Market Talk
Principaux Événements d'Actualité

Energy & Utilities Roundup: Market Talk

16 mars 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 mars 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 mars 2026, 19:53 UTC

Principaux Événements d'Actualité

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16 mars 2026, 19:43 UTC

Market Talk

Global Equities Roundup: Market Talk

16 mars 2026, 19:43 UTC

Market Talk

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16 mars 2026, 19:37 UTC

Market Talk
Principaux Événements d'Actualité

Natural Gas Follows Oil Prices Lower -- Market Talk

16 mars 2026, 19:20 UTC

Principaux Événements d'Actualité

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16 mars 2026, 19:17 UTC

Market Talk
Principaux Événements d'Actualité

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16 mars 2026, 19:00 UTC

Market Talk

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16 mars 2026, 18:23 UTC

Market Talk

LME Restarts Trading After Outage -- Market Talk

16 mars 2026, 17:36 UTC

Principaux Événements d'Actualité

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16 mars 2026, 17:19 UTC

Market Talk

Grains Sink as Investors Steer Toward Equities -- Market Talk

16 mars 2026, 17:14 UTC

Principaux Événements d'Actualité

Trump Ends News Conference

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

32.44% hausse

Prévisions sur 12 Mois

Moyen 205.89 USD  32.44%

Haut 265 USD

Bas 175 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

8

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

117.16 / 144.77Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

9 / 351Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat